Endothelial function in patients with slow coronary flow and normal coronary angiography

Signori, Luís Ulisses; Quadros, Alexandre Schaan de; Sbruzzi, Graciele; Dipp, Thiago; Lopes, Renato D.; Schaan, Beatriz D’Agord

doi:10.6061/clinics/2012(06)22

Cited by 18 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found that VD insufficiency was independently associated with SCF. Several previous studies have found a significant association between SCF and endothelial dysfunction [16]. Previous studies have reported an association between increased carotid arterial IMT and worsening coronary artery disease.…”

Section: Discussionmentioning

confidence: 97%

“…Patients with SCF are generally treated with agents such as nitrates, b-blockers, calcium channel Recently, inflammation, platelet function disorders, and imbalance in vasoactive substrates have also been implicated in the pathogenesis of the SCF phenomenon [28][29][30]. In addition, the slow-flow pattern in coronary arteries has been associated with diffuse atherosclerotic disease resulting from endothelial injury [15][16][17]; thus, SCF may be an early manifestation of diffuse atherosclerosis involving the microvascular system and epicardial coronary arteries. Moreover, traditional risk factors for cardiovascular disease, including hypertension, metabolic syndrome, diabetes mellitus, and hyperlipidemia, have been associated with SCF [31].…”

Section: Discussionmentioning

confidence: 98%

“…The majority of patients with SCF experience recurrent chest pain and most are referred for coronary angiography. Several mechanisms have been proposed to cause SCF, including microvascular and endothelial dysfunction and diffuse atherosclerosis [15][16][17].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of vitamin D insufficiency on the epicardial coronary flow velocity and endothelial function

Öz

Çizgici

Oflaz

et al. 2013

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Impact of vitamin D insufficiency on the epicardial coronary flow velocity and endothelial function

Öz

Çizgici

Oflaz

et al. 2013

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

“…These results imply that SCF patients may suffer from impairment of endothelial function. Indeed, in another independent study, Signori et al [6] claimed that SCF patients suffered from endothelial dysfunction in both arteries and veins, and implied that SCF could be a global vascular phenomenon. Furthermore, they found that the level of C-reactive protein, an independent risk factor for SCF, is significantly higher in SCF patients.…”

Section: Discussionmentioning

confidence: 99%

“…Since SCF patients have been reported to suffer from endothelial dysfunction [6,7], to evaluate the effects of HBO on SCF patients are endothelium-dependent or independent, FMD and NMD levels of patients were measured before and after HBO treatment. No remarkable difference in FMD was observed between HBO and control groups before treatment (Fig.…”

Section: Fmd and Nmd Measurementsmentioning

confidence: 99%

Effects of hyperbaric oxygen on vascular endothelial function in patients with slow coronary flow

Li¹,

Zhang

Liang

et al. 2018

Cardiol J.

View full text Add to dashboard Cite

Background: To improve therapy for slow coronary flow (SCF), the effects of hyperbaric oxygen (HBO) therapy on vascular endothelial function in divided into two groups according to the following treatment: HBO group (n = 48) and the control group (n = 50). Patients in the control group were administrated with conventional treatment, while those in the HBO group were administrated HBO therapy for 4 weeks in addition to conventional treatment. To evaluate the effects of HBO on vascular endothelial functions, plasma levels of nitric oxide (NO), calcitonin gene-related peptide (CGRP), endothelin-1 (ET-1), high sensitivity C-reactive protein (hsCRP) as well as endothelial-dependent flowmediated vasodilation (FMD) of the brachial artery were measured in both groups before and after their respective treatments.Results: There were no significant differences in plasma levels of NO, CGRP, hsCRP (Cardiol J 2018; 25, 1: 106-112)

show abstract

Telmisartan ameliorates vascular endothelial dysfunction in coronary slow flow phenomenon (CSFP)

Jin

Tan

Sun

2018

Cell Biochemistry & Function

View full text Add to dashboard Cite

Coronary slow flow phenomenon (CSFP) is a coronary microvascular disorder with an increasing morbidity, and currently, available therapies are of limited clinical value for its cure. Hence, it is urgent to find a novel approach to CSFP treatment. Several studies show that endothelial dysfunction plays a critical role in the aetiology of CSFP. Telmisartan (TMST) is a clinically available anti-hypertensive medicine and has shown its potential properties for improving vascular endothelial function. Thus, we aimed to investigate the effect of TMST on endothelial dysfunction in CSFP, Endothelial-dependent flow-mediated vasodilation, serum levels of nitric oxide, adiponectin, and endothelin-1 were surveyed before and after 3 months of TMST treatment.And the percentages of vasodilator response to acetylcholine (Ach) were detected after 12 weeks of TMST treatment. Compare with pretreatment, flow-mediated vasodilation, nitric oxide, and adiponectin were substantially improved after TMST treatment; meanwhile, endothelin-1 was decreased in the TMST group (all P < .01). Compared with the model group, the vasodilator response to Ach was enormously increased after TMST intervention. Additionally, administration of SU11274 or GW9662 would partially reverse the protective effects of TMST on accumulative concentration-vasodilator responses to Ach (P < .01). We demonstrated that administration of TMST could remarkably increase the mRNA and/or protein levels of hepatocyte growth factor, mesenchymal-epithelial transition factor, peroxisome proliferation-activated receptor γ, whereas dramatically diminish mRNA and/or protein levels of p-JNK1/2, mitogen-activated protein kinase, and nuclear factor kappa B (P < .05). Our results thus implicate that TMST ameliorates endothelial dysfunction in CSFP. It is suggested that TSMF may play an important role in the medication of CSFP.

show abstract

Endothelial function in patients with slow coronary flow and normal coronary angiography

Cited by 18 publications

References 29 publications

Impact of vitamin D insufficiency on the epicardial coronary flow velocity and endothelial function

Impact of vitamin D insufficiency on the epicardial coronary flow velocity and endothelial function

Effects of hyperbaric oxygen on vascular endothelial function in patients with slow coronary flow

Telmisartan ameliorates vascular endothelial dysfunction in coronary slow flow phenomenon (CSFP)

Contact Info

Product

Resources

About